Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Bioequivalence Study of Rivaroxaban

Condition:   Embolism, Atrial Fibrillation and Venous Thrombosis
Interventions:   Drug: Rivaroxaban (BAY 59-7939);   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsor:   Bayer
Completed - verified August 2015

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

Condition:   Embolism, Atrial Fibrillation and Venous Thrombosis
Interventions:   Drug: Rivaroxaban (BAY 59-7939);   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsor:   Bayer
Completed - verified August 2015

Atrial Fibrillation Screening With a Smartphone Device and iECG (ElectroCardioGram) Application

Condition:   Atrial Fibrillation
Intervention:   Device: iECG application
Sponsors:   Fundación Salutia;   Bayer
Not yet recruiting - verified August 2015

Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime

Conditions:   Ischemic Stroke;   Intracerebral Hemorrhage;   Oral Anticoagulation;   Cardiovascular Diseases;   Vascular Diseases
Intervention:   Other: not applicable (observational study)
Sponsors:   University Hospital Heidelberg;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma;   Boehringer Ingelheim;   Bristol-Myers Squibb;   Institute of Clinical Epidemiology and Biometry, University of Würzburg, Germany (for biometry and data management)
Recruiting - verified August 2015

Evaluation of Rapid Emergency Echography for Acute Dyspnoea

Condition:   Acute Dyspnea
Intervention:   Device: Echocardiography according to the READ method.
Sponsors:   Centre Hospitalier Universitaire de Besancon;   Centre Hospitalier Germon et Gauthier;   University Hospital, Clermont-Ferrand;   Centre Hospitalier de PAU;   Centre Hospitalier Universitaire de Strasbourg;   Centre Hospitalier Général de Toulon
Not yet recruiting - verified August 2015

Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation

Conditions:   Heart Failure;   Recurrent Atrial Fibrillation
Interventions:   Procedure: AVATAR-AF ablation;   Drug: Anti-Arrhythmic therapy;   Procedure: Conventional AF ablation
Sponsor:   Imperial College London
Recruiting - verified August 2015

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program

Condition:   Non-valvular Atrial Fibrillation
Interventions:   Drug: Xarelto;   Other: Experimental: Personalized information intervention
Sponsor:   University Hospital, Montpellier
Active, not recruiting - verified August 2015

Canadian WATCHMAN Registry

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Cardiology Research UBC
Recruiting - verified August 2015

Impedance vs. Contact Force Guided Atrial Fibrillation Ablation Using Automated Annotation System

Condition:   Atrial Fibrillation
Intervention:   Device: Ablation
Sponsors:   Keimyung University Dongsan Medical Center;   Biosense Webster, Inc.
Recruiting - verified August 2015

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Condition:   Atrial Fibrillation
Interventions:   Drug: Warfarin;   Drug: Dabigatran Etexilate 150mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2015

Outcome of Different Ablation Strategies In Persistent and Long-Standing Persistent Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Procedure: radiofrequency catheter ablation
Sponsor:   Texas Cardiac Arrhythmia Research Foundation
Recruiting - verified August 2015

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran etexilate;   Drug: Phenprocoumon
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

Eagle AF (Atrial Fibrillation) - Endoscopically Guided Laser Ablation of Persistent Atrial Fibrillation

Condition:   Persistent Atrial Fibrillation
Intervention:   Device: Endoscopically guided laser ablation HeartLight system
Sponsor:   Prof. Dr. med. Bernd Lemke
Recruiting - verified August 2015

The Ottawa AF Cardioversion Protocol

Condition:   Atrial Fibrillation
Intervention:   Device: Lifepak 20E Defibrillator, Licence No: 61944
Sponsor:   David Birnie
Recruiting - verified August 2015

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2015

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Condition:   Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Sotalol;   Drug: Placebo for BMS-919373
Sponsor:   Bristol-Myers Squibb
Recruiting - verified August 2015

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Condition:   Atrial Fibrillation
Interventions:   Drug: Phenprocoumon (Marcumar);   Drug: Rivaroxaban (Xarelto, BAY-59 7939)
Sponsor:   Bayer
Completed - verified August 2015

Stroke Feasibility Study

Conditions:   Atrial Fibrillation;   AFib
Intervention:   Device: AtriClip LAA Exclusion Device
Sponsor:   AtriCure, Inc.
Completed - verified August 2015

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Condition:   Current or Recent History of Atrial Fibrillation
Interventions:   Drug: bucindolol hydrochloride;   Drug: metoprolol succinate
Sponsors:   ARCA Biopharma, Inc.;   Medtronic
Recruiting - verified September 2015

Registry on WATCHMAN Outcomes in Real-Life Utilization WASP Registry

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boston Scientific Corporation
Recruiting - verified August 2015

Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study

Conditions:   Atrial Fibrillation;   Coronary Artery Disease
Intervention:   Drug: OAC alone
Sponsors:   Satoshi Shizuta;   Research Institute for Production Development;   Daiichi Sankyo Co., Ltd.
Recruiting - verified August 2015

Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo

Condition:   Atrial Fibrillation
Interventions:   Drug: citrate of caffeine;   Drug: placebo
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified August 2015

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Condition:   Atrial Fibrillation
Intervention:   Drug: Pradaxa, dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2015

Anticoagulant Utilization Pattern

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Condition:   Atrial Fibrillation
Intervention:   Drug: Pradaxa (Dabigatran etexilate mesilate)
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: ISIS CRP Rx;   Drug: Placebo
Sponsor:   Isis Pharmaceuticals
Completed - verified August 2015

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Condition:   Atrial Fibrillation
Intervention:   Other: Patients with Atrial Fibrillation
Sponsors:   Janssen Scientific Affairs, LLC;   Duke Clinical Research Institute
Recruiting - verified August 2015

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)

Conditions:   Stroke, Acute;   Atrial Fibrillation
Intervention:   Other: This is an observational study.
Sponsor:   Ministry of Health, Labour and Welfare, Japan
Active, not recruiting - verified August 2015

Left Atrial Appendage Occlusion Study III

Conditions:   Cardiac Surgery With Cardiopulmonary Bypass;   Atrial Fibrillation
Intervention:   Other: Left Atrial Appendage Occlusion
Sponsor:   Population Health Research Institute
Recruiting - verified August 2015

Ventricular Pace Suppression Versus Intrinsic Rhythm Support Study

Condition:   Sick Sinus Syndrome
Interventions:   Other: Ventricular Pace Suppression (Vps);   Other: Intrinsic rhythm support (IRSplus)
Sponsor:   Biotronik SE & Co. KG
Active, not recruiting - verified August 2015

Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Drug: Prazaxa
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified August 2015

Kansai Plus Atrial Fibrillation Trial

Condition:   Atrial Fibrillation
Interventions:   Procedure: ATP guide additional ablation.;   Drug: Antiarrhythmic drug (AAD);   Procedure: ATP guide additional ablation.;   Drug: Control;   Procedure: Control;   Drug: Antiarrhythmic drug (AAD);   Procedure: Control;   Drug: Control
Sponsor:   Kyoto University, Graduate School of Medicine
Active, not recruiting - verified August 2015

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

Conditions:   Coronary Artery Disease;   End Stage Renal Disease
Intervention:   Drug: Nicorandil (15mg/day)
Sponsor:   Kumamoto University
Active, not recruiting - verified August 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Conditions:   Anti-coagulation Therapy;   DVT;   Pulmonary Embolism;   Joint Surgery Multiple;   Atrial Fibrillation;   Prosthetic Replacement of Mitral Valve
Intervention:   Device: Warfarin GenoSTAT Test
Sponsor:   Iverson Genetic Diagnostics, Inc.
Suspended - verified August 2015

Use of the Hansen Medical System in Patients With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Device: Ablation
Sponsor:   Hansen Medical
Recruiting - verified August 2015

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure

Conditions:   Sleep Apnea;   Heart Failure
Intervention:   Device: Adaptive Servo Ventilation
Sponsors:   Toronto Rehabilitation Institute;   Canadian Institutes of Health Research  (CIHR);   Philips Respironics
Recruiting - verified August 2015

Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study

Conditions:   Obstructive Sleep Apnea;   Atrial Fibrillation
Intervention:   Device: Implantable Loop Recorder Insertion
Sponsors:   Queen's University;   Medtronic
Recruiting - verified August 2015

Get CardioSmart

You're Invited

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points